DOSES STUDIED
The Ipamorelin doses the studies actually used — and why the half-life shapes them.
Every dose here is reported as it appeared in a published study, in its species and by its route. No human dosing is given.
How to read this page
This is a research-context summary of the Ipamorelin doses used in published studies — not a protocol and not a recommendation. Think of it as a record of what scientists administered, to which animal or volunteer, by which route, and for how long. No line here tells anyone what to take. The thread that ties it together is the pharmacokinetics: because Ipamorelin clears with a roughly two-hour half-life and fires a single growth-hormone pulse about forty minutes after dosing [2], the studied regimens cluster around brief, repeated exposures rather than steady infusions. Where community "stack" protocols are mentioned, they are flagged as anecdotal with no peer-reviewed human dosing basis. Doses appear in the original units (nmol/kg, micrograms/day, mg/kg) exactly as the studies reported them.
The human doses that were studied
Two human datasets define the Ipamorelin dose record, and only two. The pharmacokinetic study gave healthy male volunteers single intravenous infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes, establishing dose-proportional kinetics and the roughly two-hour half-life [2]. The Phase 2 ileus trial gave bowel-resection patients 0.03 mg/kg intravenously twice daily for up to seven days [3]. That is the entire controlled human dosing literature — acute single IV doses for kinetics, and a one-week perioperative IV regimen that failed its efficacy endpoint. There is no human subcutaneous dosing study, despite subcutaneous injection being the dominant route in off-label community use.
The animal dose-response data
Animal studies provide the dose-response detail. The bone-growth study administered 18, 90, and 450 micrograms/day subcutaneously, divided three times daily for 15 days, in adult female rats, and saw a clean step-up in longitudinal bone growth across those three levels [4]. A separate bone-mineral study used 0.5 mg/kg/day by continuous subcutaneous osmotic minipump over 12 weeks. Postoperative-ileus rodent work used 0.1 to 1 mg/kg intravenously, repeated four times daily. The 2024 ferret cachexia study used 1 to 3 mg/kg intraperitoneally [5]. Across these, the pattern is repeated short exposures or, in the minipump case, a low continuous rate — consistent with a short-half-life peptide whose effect is the GH pulse it triggers, not sustained blood levels.
How much cjc-1295 ipamorelin
How much cjc-1295 ipamorelin a person should use is not a question the published literature answers, and this site gives no figure. There is no controlled human dosing study of the combination — the popular subcutaneous "stack" protocols circulating in peptide communities have no peer-reviewed human dosing basis and must be read as anecdotal, not recommended [3]. What the science offers is mechanism, not a number: GHRH analog plus GHRP synergy in animals [12], and Ipamorelin's own ~2-hour human half-life from single IV doses [2]. Any specific milligram figure online traces to community convention, not to a trial. The honest answer is that no validated human dose exists.
Routes and bioavailability, by the numbers
The studied routes span intravenous (the human PK and clinical work, plus rodent efficacy), subcutaneous (rodent bone and body-composition studies, and the dominant community route), intranasal (rodent PK, with about 20% bioavailability [10]), and intraperitoneal (rodent and ferret efficacy [5]). Ipamorelin itself is not orally bioavailable — only engineered Ipamorelin-derived analogs reached around 10% oral absorption in dogs. In male rats, Ipamorelin showed roughly 5-fold lower plasma clearance than GHRP-6, with 60-80% of the dose recovered intact in bile and urine, indicating moderate metabolic stability [10]. These figures are pharmacology, reported third-person; none of them constitutes a dosing instruction.
How to reconstitute cjc-1295 ipamorelin 5mg
How to reconstitute cjc-1295 ipamorelin 5mg is a research-handling question, and only general peptide-handling observations from the research-supply literature can be offered here — not a clinical preparation instruction. Ipamorelin is supplied as a lyophilized (freeze-dried) powder, either as the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling [2]. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated. This site does not provide volumes, concentrations, or a step-by-step preparation method, because doing so would cross into dosing guidance. The published record characterizes the powder form and its stability, not a use protocol.
Why the kinetics make duration matter
The roughly two-hour terminal half-life is why study durations and timing matter more than any single dose figure [2]. A short half-life means each dose produces one transient GH pulse and then clears; the GH response peaks near 40 minutes and resolves, rather than building a sustained plateau [2]. That is why rodent efficacy regimens used repeated daily dosing or continuous minipump delivery, and why the human trial dosed twice daily [3]. For the full elimination curve, see how long does ipamorelin stay in your system; for the onset and effect timeline, see how long does it take for ipamorelin to work.